

Nadine Krger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4508847/nadine-kruger-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

12,399
citations

15
h-index

35
g-index

35
ext. papers

16,995
ext. citations

13.9
avg, IF

7.14
L-index

#	Paper	IF	Citations
30	Alternatives to animal models and their application in the discovery of species susceptibility to SARS-CoV-2 and other respiratory infectious pathogens: A review.. <i>Veterinary Pathology</i> , 2022 , 3009858211073678	28.1	1073678
29	Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.. <i>MBio</i> , 2022 , e0036422	7.8	0
28	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.. <i>Cell</i> , 2021 ,	56.2	156
27	Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. <i>EBioMedicine</i> , 2021 , 65, 103255	8.8	120
26	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021 , 184, 2384-2393.e12362	56.2	459
25	SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. <i>Cell Reports</i> , 2021 , 35, 109017	10.6	42
24	Therapeutic Application of Alpha-1 Antitrypsin in COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 224-227	10.2	15
23	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021 , 36, 109415	10.6	131
22	Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. <i>Chemical Science</i> , 2021 , 12, 12600-12609 ²	9.4	12609 ²
21	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021 , 37, 109825	10.6	31
20	The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
19	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. <i>Cell</i> , 2020 , 181, 271-280.e8	56.2	10629
18	Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. <i>Emerging Microbes and Infections</i> , 2020 , 9, 155-168	18.9	53
17	Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity 2020 ,		30
16	Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. <i>Nature</i> , 2020 , 585, 588-590	50.4	243
15	Fusogenicity of the Ghana Virus (:) Fusion Protein is Controlled by the Cytoplasmic Domain of the Attachment Glycoprotein. <i>Viruses</i> , 2019 , 11,	6.2	5
14	Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins. <i>PLoS ONE</i> , 2019 , 14, e0214968	3.7	1

13	Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells. <i>Journal of Virology</i> , 2019 , 93,	6.6	14
12	Entry, Replication, Immune Evasion, and Neurotoxicity of Synthetically Engineered Bat-Borne Mumps Virus. <i>Cell Reports</i> , 2018 , 25, 312-320.e7	10.6	9
11	The Sialic Acid Binding Activity of Human Parainfluenza Virus 3 and Mumps Virus Glycoproteins Enhances the Adherence of Group B Streptococci to HEp-2 Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018 , 8, 280	5.9	11
10	Recombinant mumps viruses expressing the batMuV fusion glycoprotein are highly fusion active and neurovirulent. <i>Journal of General Virology</i> , 2016 , 97, 2837-2848	4.9	3
9	The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells. <i>PLoS ONE</i> , 2016 , 11, e0152134	3.7	19
8	Functional properties and genetic relatedness of the fusion and hemagglutinin-neuraminidase proteins of a mumps virus-like bat virus. <i>Journal of Virology</i> , 2015 , 89, 4539-48	6.6	14
7	Attachment protein G of an African bat henipavirus is differentially restricted in chiropteran and nonchiropteran cells. <i>Journal of Virology</i> , 2014 , 88, 11973-80	6.6	9
6	Characterization of African bat henipavirus GH-M74a glycoproteins. <i>Journal of General Virology</i> , 2014 , 95, 539-548	4.9	18
5	Surface glycoproteins of an African henipavirus induce syncytium formation in a cell line derived from an African fruit bat, <i>Hypsignathus monstrosus</i> . <i>Journal of Virology</i> , 2013 , 87, 13889-91	6.6	19
4	The Omicron variant is highly resistant against antibody-mediated neutralization [Implications for control of the COVID-19 pandemic]		13
3	The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells		284
2	SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination		48
1	Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination		